Selank and Semax: Russian CNS peptides for athletes

Selank and Semax sit in a corner of the peptide market that most strength-focused readers never visit: short CNS peptides developed by the Russian Academy of Medical Sciences in the late Soviet era for anxiety and cognitive support, prescription drugs in Russia today, and research chemicals everywhere else. They have nothing to do with muscle, tendon, or fat loss. So why do they keep showing up in athlete peptide stacks?

The answer is the part of athletic performance that doesn't get talked about as much as recovery and hypertrophy: the central nervous system. The mental component of training — focus, anxiety regulation, sleep quality, motivation — is fragile under volume. Selank and Semax aim straight at that fragility. Whether they hit is a more complicated question.

What these molecules are

Both peptides come out of the same lineage of Russian peptide pharmacology, and both are derived from natural endogenous neuropeptides.

Selank is a synthetic analog of tuftsin, a four-amino-acid immunomodulatory peptide that exists naturally in human IgG. Selank's full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The modifications extend tuftsin's half-life and produce a peptide with primary anxiolytic activity along with immune-modulating effects.

Semax is a synthetic analog of ACTH (4-10), a fragment of adrenocorticotropic hormone that, in its native form, has cognitive and neurotrophic effects without the cortisol-driving activity of full ACTH. Semax's sequence is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The modifications extend half-life and bias activity toward cognitive and neuroprotective effects.

Both are short — 7 amino acids each — and both were developed in the same Russian research environment, which is why they tend to be discussed together.

In Russia, both are listed in the State Register of Medicines and used clinically — Selank for generalized anxiety, Semax for cognitive recovery after stroke and as a pediatric attention support drug. Neither has FDA approval in the US, and outside of Russia they exist in regulatory limbo.

What the evidence actually shows

The published research is a mix of Russian-language journals (much of it not indexed in PubMed) and a smaller body of English-language work. Quality varies.

Selank — anxiolytic effect. A modest set of human trials in Russia has compared Selank to benzodiazepines and to placebo in generalized anxiety populations. Results suggest anxiolytic activity comparable to medazepam without the sedation or dependence profile typical of benzodiazepines. Sample sizes are small and blinding quality is inconsistent. Independent replication outside Russia is limited.

Selank — immune modulation. Animal data shows effects on cytokine balance and IgG/IgA production. The clinical relevance to a healthy athlete is unclear.

Semax — cognitive and neurotrophic. Better-studied of the two. Russian clinical work suggests benefit in stroke recovery and ADHD-like presentations in children. Mechanistic work shows effects on BDNF (brain-derived neurotrophic factor), dopaminergic and serotonergic systems, and neuroprotection in ischemia models.

Semax — exercise tolerance. A few small studies have looked at Semax in athletes under fatigue conditions, with positive but underpowered signals for cognitive performance and mood under stress.

The honest summary: there is some clinical and preclinical evidence for both, but it's geographically concentrated, often methodologically weaker than Western pharmacological trials, and operates on endpoints (anxiety, cognition) that are harder to measure objectively than muscle mass or visceral fat.

The route-of-administration problem

This is the part most community write-ups gloss over.

Both Selank and Semax are typically administered intranasally in Russian clinical use. The original formulations were designed for nasal delivery — peptides this short, polar, and rapid-clearance don't survive oral administration, and subcutaneous injection of peptides this short produces a brief plasma spike rather than the sustained CNS exposure you want for either drug.

The research-chemical market often sells these peptides as subcutaneous injection products, sometimes with little or no guidance on nasal preparation. That mismatch matters because:

• Subcutaneous injection puts the peptide in plasma, not CSF or directly into nasal epithelium where the original clinical pharmacology was characterized
• The Russian clinical doses are defined for nasal spray formulations, not for injection
• "Selank 250 mcg SubQ daily" — a common community protocol — doesn't map cleanly to any Russian clinical dose schedule

Some experienced users prepare a nasal spray from research-chemical vials and dose intranasally. This is closer to the original pharmacology but requires more care around sterility, pH, and preservative chemistry than most users invest in. It's also one of the few cases in the peptide space where the route, not just the dose, is doing serious work in the protocol.

Where they might fit for athletes

If the route question is handled properly, there are a few use cases where these compounds plausibly help athletes:

High-volume training blocks with rising anxiety or sleep disruption. Selank's anxiolytic effect, if it translates outside Russian clinical populations, would target the same nervous-system overload that drives non-physical overtraining symptoms. For the broader context on CNS fatigue see sleep quality, peptides, and the hygiene gap and DSIP for sleep architecture in athletes.

Competition prep anxiety. Used short-term, Selank's profile (anxiolytic without sedation, no clear dependence pattern) is interesting for pre-competition cognitive load. The non-sedating part matters for sports where reaction time matters.

Cognitively demanding work alongside hard training. Semax's cognitive and neurotrophic signals, if real, would matter for athletes who are also doing demanding non-physical work — students, professionals — and finding their cognitive bandwidth drained by training. The evidence is thinner than for Selank's anxiolytic claim, but the use case is real.

Recovery from concussive or sub-concussive stress. Combat-sports athletes, contact-sport athletes, and others with repeated CNS insults have shown interest in Semax for the neuroprotective angle. The animal data is suggestive; the human evidence in this specific context is essentially absent.

For the broader frame on integrating CNS-acting peptides with the rest of a strength-peptide program, see building your first peptide protocol and periodizing peptide cycles to training.

Where they don't fit

These are not muscle-building, fat-loss, or tendon-healing peptides. Despite occasional marketing claims, they don't substitute for or stack synergistically with BPC-157, TB-500, GH secretagogues, or IGF-1 in any direct physiological sense. They occupy a parallel domain (CNS) rather than a competing one.

If your primary goals are body composition or injury recovery, Selank and Semax are off-topic for the budget and time you have. Use the budget on the peptides where the data and the goal are aligned.

Stacking considerations

Some users combine Selank and Semax — anxiolytic plus cognitive — under the theory that the two effects are complementary. The mechanistic case is reasonable but the empirical case is thin. There is no clinical literature evaluating the combination specifically.

What's worth flagging:

• Don't combine with sedatives (alcohol, benzodiazepines, sleep medications) without thinking about it. Selank's effect on GABAergic signaling, while modest, isn't zero.
• Don't combine with stimulant pre-workouts in high doses. Semax has some interaction with monoaminergic systems; piling a strong stimulant on top is a recipe for unpredictable response.
• Cycle awareness. Both peptides are typically used in courses (2–4 weeks on, then off) rather than continuously. Tolerance development isn't well-characterized but the structure parallels other CNS-acting compounds.

Sourcing and quality

These short peptides are technically easy to synthesize, which is both good and bad: easy synthesis means more vendors offer them, but it also means quality control varies widely.

What to insist on:

• A COA showing the correct sequence (TKPRPGP for Selank, MEHFPGP for Semax)
• Purity by HPLC ≥ 98%
• Mass spectrometry confirming molecular weight
• Identifiable vendor with shipping and storage practices appropriate for short peptides

For the framework on evaluating vendors, see vendor due diligence checklist.

The honest framing

Selank and Semax are real drugs in their country of origin and interesting compounds elsewhere. They have specific, narrow use cases for athletes: CNS overload, competition anxiety, cognitive demands stacked on top of training. They are not part of the standard strength-peptide toolkit, and most strength-focused users will get better return on attention and budget elsewhere.

If you do explore them, the route of administration is the critical variable most users get wrong. And if you're not already at the point where the psychological and cognitive dimensions of your training are limiting factors — versus the physical ones — these peptides are too far up the stack to be worth your time.

Related reading

• Sleep quality, peptides, and the hygiene gap
• DSIP for sleep architecture in athletes
• Building your first peptide protocol
• Vendor due diligence checklist